DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

Climate change is on track to reduce by 11 percent in 2100 the yields that today provide two-thirds of humanity's calories ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

Cassava Sciences Inc. stock grades by Barron's. View SAVA fundamental and sentiment analysis powered by MarketGrader.

NEW YORK, March 26 (Reuters) - The biotechnology company Cassava Sciences (SAVA.O), opens new tab failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who ...

AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation of all ongoing trials. Read more here.

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.